Millennium and Seattle Genetics have announced successful clinical results from two Phase II trials of Adcetris (brentuximab vedotin) in relapsed or refractory Hodgkin’s lymphoma patients.

The dose-escalation trials included 20 patients and demonstrated the activity and tolerability of the drug.

Seattle Genetics chief medical officer Thomas Reynolds said that the findings from the trial indicated that the drug benifitted patients for whom standard second-line induction therapy is not an option or has failed to produce a robust response prior to autologous stem cell transplant.

The adverse events seen with the drug were fatigue, nausea, fever, weight loss and diarrhoea.

The results were presented at the 16th Congress of the European Hematology Association in London earlier this month.